Bi-layered Wound Dressings: Integrating Tranexamic Acid for Rapid Hemostasis and Antibacterial Defense

Study Background and Research Question

Traumatic injuries are a leading cause of mortality, with uncontrolled hemorrhage and subsequent infection accounting for a substantial proportion of early deaths, particularly within the first 72 hours post-injury. Traditional wound dressings often struggle to simultaneously address rapid blood loss and infection risk. Tranexamic Acid, a synthetic antifibrinolytic agent, is established for its ability to competitively inhibit plasminogen activation and subsequently suppress fibrinolysis, stabilizing blood clots in both systemic and topical applications. However, integrating antifibrinolytic and antibacterial strategies within a single wound dressing has remained a technical challenge. The primary research question posed by the reference study is whether a novel bi-layer dressing, combining Tranexamic Acid, nitric oxide (NO) release, and propolis, can deliver immediate hemostasis alongside robust antibacterial protection in the context of traumatic injuries.

Key Innovation from the Reference Study

The study introduces a bi-layer wound dressing system (T-SP) that strategically leverages the distinct properties of three components: Tranexamic Acid (TXA), S-nitroso-N-acetylpenicillamine (SNAP, an NO donor), and propolis. The innovation lies in the spatial arrangement and synergy of these agents:

• Hemostatic Layer: TXA is uniformly suspended within a resinous bed of propolis, directly contacting the wound surface. This configuration targets immediate clot stabilization by preventing fibrin breakdown.
• Base Layer: SNAP is embedded in a Carbosil® polymer matrix, delivering controlled NO release for antibacterial action and support of wound healing.
• Propolis Integration: Serving as both a bioadhesive and an additional antibacterial/anti-inflammatory agent, propolis enhances the local therapeutic environment.

This bi-layer approach is designed to address the dual clinical priorities of rapid bleeding control and infection prevention in a single, deployable dressing system, as described in the reference study.

Methods and Experimental Design Insights

The fabrication process involved sequential layering:

• The wound-contacting upper layer was prepared by suspending TXA at varying concentrations (2.5%, 5.0%, and 7.5% v/v) in propolis, then applying this mixture onto a substrate.
• The base layer, located further from the wound, consisted of SNAP dispersed within a Carbosil® copolymer blend, enabling sustained NO release.

Experimental evaluation focused on two primary domains:

• Hemostasis: Platelet adhesion and fibrin activation were quantified using a lactate dehydrogenase (LDH)-based assay. Clot structure and stability were further assessed by scanning electron microscopy (SEM), visualizing the density and organization of the fibrin network.
• Antibacterial Efficacy: Dressings were tested against both Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii, with bacterial colony-forming units (CFU) enumerated after exposure to the dressings.

Protocol Parameters

• Tranexamic Acid formulation: Applied at 2.5%, 5.0%, and 7.5% v/v within the propolis resin; 7.5% yielded optimal fibrin activation.
• NO donor loading: SNAP incorporated into Carbosil® base layer; release kinetics tailored for sustained NO delivery.
• Platelet adhesion assay: LDH-based quantification performed within 15 minutes post-application to simulate acute hemostatic response.
• Bacterial challenge: Dressings challenged with clinical isolates of S. aureus and A. baumannii for assessment of antibacterial performance.

Core Findings and Why They Matter

The bi-layer T-SP dressing demonstrated several notable outcomes:

• Rapid Clot Formation: The 7.5% TXA–propolis top layer significantly increased fibrin activation within the first 15 minutes, as measured by the LDH assay. SEM imaging confirmed a dense, stabilized fibrin network supporting the clot structure.
• Effective Inhibition of Fibrinolysis: TXA's presence hindered plasmin-mediated clot breakdown, enhancing stability and reducing the likelihood of rebleeding—key for hemorrhage control in trauma scenarios.
• Potent Antibacterial Activity: Combined NO and propolis effects achieved a 98.9 ± 1% reduction in S. aureus CFU and a 99.4 ± 1% reduction in multidrug-resistant A. baumannii, highlighting the ability to address wound infection risks alongside hemostasis.

These findings are significant as they provide a proof-of-concept for integrating antifibrinolytic and antibacterial mechanisms within a deployable wound dressing suitable for emergency and battlefield contexts. The dual-action approach has the potential to improve patient outcomes by addressing the two most pressing complications following traumatic injury.

Comparison with Existing Internal Articles

Recent internal literature, including "Tranexamic Acid in Fibrinolysis Research: Applied Protocols & Innovations", emphasizes Tranexamic Acid's role as an antifibrinolytic agent for stabilizing clots and modeling hemostasis in both in vitro and preclinical wound care assays. The referenced study extends these principles by integrating TXA into a functional biomaterial, demonstrating its utility beyond conventional liquid or powder delivery forms. Similarly, "Tranexamic Acid: Mechanistic Leverage for Translational Hemostasis" discusses the translation of antifibrinolytic mechanisms into trauma wound care, mirroring the strategy executed in the T-SP dressing. The current study distinguishes itself by validating the synergy of antifibrinolytic activity and antibacterial protection within a single, deployable dressing format, supporting a next-generation approach to trauma management.

Limitations and Transferability

While the bi-layer dressing demonstrates clear efficacy in vitro and ex vivo models, several limitations warrant consideration. The direct clinical applicability requires further validation in animal trauma models and human trials, particularly regarding the biocompatibility of SNAP and the long-term safety of NO release in wound environments. Additionally, the optimal concentration and release kinetics of TXA and NO will need adjustment for different wound types and patient populations. Transferability to chronic wounds or non-traumatic injury settings has not been established and should be approached cautiously.

Research Support Resources

To replicate or expand upon these workflows, researchers require high-purity Tranexamic Acid suitable for both solution and biomaterial integration. Tranexamic Acid (SKU B1858) from APExBIO offers well-documented quality control and solubility data, making it appropriate for in vitro, ex vivo, and translational fibrinolysis research. When formulating clot-stabilizing biomaterials or performing plasmin-induced neutrophil adherence assays, reliable antifibrinolytic agents are critical for reproducibility and mechanistic clarity. Investigators are advised to consult both the product information and relevant protocol literature to optimize their experimental designs.